Navigation Links
Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
Date:11/28/2012

igible to receive a royalty on net sales of temanogrel in South Korea, while Ildong is eligible to receive a share of future payments received by Arena related to licensing transactions and sales of temanogrel in other territories.

"It is a great pleasure to establish this collaboration with Arena for temanogrel," said Jung-chi Lee, Ildong's Chairman and Chief Executive Officer. "We look forward to supporting the global development of this drug candidate and having the opportunity to bring temanogrel to patients in South Korea as a treatment for thrombotic diseases."

About ThrombosisThrombosis is the formation of a clot, or thrombus, inside a blood vessel. Thrombus formation that occurs in the blood vessels of the heart or brain can lead to serious thrombotic diseases including myocardial infarction, acute coronary syndrome and stroke. One of the initial events in thrombus formation is the activation of platelets, which then aggregate and adhere to one another as they release certain factors, including high concentrations of serotonin. Serotonin promotes further platelet aggregation and also causes constriction, or narrowing, of the blood vessels. Elevated serotonin levels have been associated with increased cardiovascular risk. The prothrombotic effects of serotonin on platelets and blood vessels are mediated by the serotonin 2A receptor, and inverse agonists of the serotonin 2A receptor have the potential to inhibit this activity.

About TemanogrelTemanogrel is an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, and has completed single- and multiple-ascending dose Phase 1 trials in healthy volunteers. Temanogrel has the potential to prevent serotonin-mediated platelet aggregation and reverse serotonin-mediated vasoconstriction. This dual mechanism of temanogrel may be therapeutically useful for the treatment or prevention of thrombotic diseases.

About Arena PharmaceuticalsArena Pharmaceuti
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
2. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
4. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
5. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
6. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
9. Arena Pharmaceuticals Files Marketing Authorization Application in Switzerland for Lorcaserin as a Treatment for Weight Control
10. Arena Pharmaceuticals to Present at the Seventh Annual JMP Securities Healthcare Conference
11. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the list of stocks featured in the Analyst Blog. Every ... and events impacting stocks and the financial markets. Stocks recently ... Free Report ), Gilead (Nasdaq: GILD - Free Report ... AbbVie (NYSE: ABBV - Free Report ) and Celgene ... Zacks is promoting its ,Buy, stock recommendations. Get #1Stock ...
(Date:7/31/2014)... For the first time, cardiac surgeons, medical ... the SynCardia temporary Total Artificial Heart in a peer ... the Journal of Visualized Experiments website. ... the SynCardia Total Artificial Heart implantation   goo.gl/2OZyKW ... the SynCardia Total Artificial Heart," a July 18, 2014 ...
(Date:7/31/2014)... , July 31, 2014 Astellas has ... of corporate and employee communications in the Americas ... Winton , senior vice president, chief communications officer. ... developing and leading corporate brand initiatives and reputation ... North and South America . ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... options and research directions , , WASHINGTON, June ... therapeutic option for many patients with interstitial cystitis (IC). IC ... 8 million women and 1.5 million men in the United ... noticed a correlation between allergies and IC. Recently, a urologist ...
... Families of Spinal Muscular Atrophy has just released details ... funded therapeutic pipeline. , , Families of SMA ... Quinazolines to boost gene expression; 2) Tetracyclines at Paratek ... replacement program at California Stem Cell and UCI. ...
Cached Medicine Technology:Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 2Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 3Urologist and Allergist Explore Link Between Allergies and Interstitial Cystitis 4Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 2Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs 3
(Date:7/31/2014)... Mountain View, Calif. and Las Vegas, Nevada (PRWEB) July ... a partnership with LaunchKey to provide next generation authentication ... a simple and secure way to utilize hardware protected ... an enormous problem in the Internet's reliance on password-based ... of hacks and global data breaches taking place around ...
(Date:7/31/2014)... 2014 The Beryl Institute announces three ... and four new members of its Patient ... the global community of practice and premier thought leader ... Executive board members are industry leaders who advise on ... insight into market and industry trends. The advisory board ...
(Date:7/31/2014)... 31, 2014 Web Programming Services, a ... certified internet marketing firm, has recently launched a new ... this service affordable for everyone, the company has announced ... , Web Programming Services has tailored the service ... brochure designing and likely expectations of the clients from ...
(Date:7/31/2014)... HealthDay Reporter , WEDNESDAY, July 30, ... isn,t warranted based on current evidence, a team of ... compete with regular cigarettes might cut tobacco-related deaths and ... on the use and safety of the nicotine-emitting devices. ... a potential for smokers to reduce their health risks ...
(Date:7/31/2014)... New Delhi, India (PRWEB) July 31, 2014 ... company has launched a new online reputation management ... help individuals as well as organizations get rid ... service is the result of extensive research. ReputationChief.Com ... design a service for those who are struggling ...
Breaking Medicine News(10 mins):Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 2Health News:Rivetz Partners with LaunchKey to Offer Next Generation Authentication for Accounts Leveraging Trusted Execution Technology. 3Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 2Health News:The Beryl Institute Announces Seven New Patient Experience Board Members 3Health News:Web Programming Services Introduces Affordable Brochure Designing Service 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:ReputationChief.Com Announces a New Online Reputation Management Service 2
... , MONDAY, April 11 (HealthDay News) -- Progressive resistance ... to function better in daily life, researchers say. A ... review of available evidence and concluded that an adult can ... and increase their overall strength by 25 percent to 30 ...
... Ore. An Oregon Health & Science University researcher has ... prevent rejection in organ transplant patients helped treat a rare ... cure and, until now, no known treatment. The clinical ... first randomized, controlled study designed to develop a therapy for ...
... By Steven Reinberg HealthDay Reporter , MONDAY, April ... engines cuts emissions of heart-harmful microscopic particles by 98 percent, ... new study suggests. The very tiny particles found in ... heart disease caused by air pollution, but "if we use ...
... treatment for osteoporosis has often been associated with serious ... Sweden, have now, in mice, found a way of ... that only the skeleton is acted on, current research ... in the respected journal PNAS (Proceedings of the National ...
... A study appearing in the journal Investigational New Drugs ... that two new small molecule inhibitors are showing promise ... common malignant bone tumor, osteosarcoma. These small molecule inhibitors ... spice may serve as a new, non-toxic treatment ...
... Nearly all patients with advanced cancer experience severe pain, and ... regardless of the type or stage of the disease. Pain ... new study, led by Wayne State University,s College of Nursing ... Cancer Institute of the National Institutes of Health, aims to ...
Cached Medicine News:Health News:Progressive Weight Training Can Boost Seniors' Strength 2Health News:OHSU expert co-authors study finding treatment for rare lung disease 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 2Health News:Emissions Trap Cuts Harmful Diesel Pollution 3Health News:New study finds compounds show promise in blocking STAT3 signaling as treatment for osteosarcoma 2Health News:Wayne State leads study to improve management of cancer pain in African Americans 2
BD Vacutainer® Specialty Tubes - Acid Citrate Dextrose (ACD)...
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
The Erythrocyte Sedimentation Rate (ESR) can be used as a nonspecific search technique in case of suspicion of inflammatory reactions as well as for judgement of their development. VACUETTE® ESR...
Medicine Products: